| Funding Opportunity ID: |
325378 |
| Opportunity Number: |
RFA-HL-21-007 |
| Opportunity Title: |
Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (U24 Clinical Trial Optional) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.839 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Mar 12, 2020 |
| Close Date: |
Jun 08, 2020 |
| Last Updated Date: |
Mar 12, 2020 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
$547,992 |
| Expected Number of Awards: |
1 |
| Description: |
This limited competition Funding Opportunity Announcement (FOA) seeks an application from the current Sickle Pan-African Research Consortium (SPARCO) Hub in Tanzania to continue coordinating, as the Clinical Coordinating Center (CCC), activities of the renewed and expanded Consortium (SPARCO), including the 3 established sites in Ghana, Nigeria and Tanzania as well as up to 3 new Consortium sites located in additional sub-Saharan African nations. Together, the CCC, the Sickle Africa Data Coordinating Center (SADaCC, see RFA-HL-21-008), as well as established and new sites of the Consortium (RFA-HL-21-009) will constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Network. This network aims to develop a sustainable resource that will advance sickle cell disease related epidemiologic, translational, and clinical research studies. The SPARCO CCC application needs to propose a feasible and meritorious plan for expanding a sickle hemoglobinopathy registry database that can facilitate patient tracking and follow-up and serve as a backbone for future SCD research. In particular, this FOA seeks an application that proposes to identify database elements and plans for harmonization of SCD phenotype definitions and ontologies, and integration of Collaborative Consortium activities with those of the DCC (SADaCC), NHLBI, Steering Committee, Observational Study Monitoring Board (OSMB), and existing training programs. The application needs to describe approaches to the development of regionally appropriate standards of SCD care, as well as approaches to the organization of research and clinical skill development activities. The application also needs to include coordination of Consortium sites to allow for development, implementation, and conduct of SCD cohort studies, as well as implementation research of preventive/ therapeutic practices. |
| Version: |
1 |
|
